Latest Conference Articles

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses how small molecule inhibitors are used in atopic dermatitis, as well as why there is no one-size-fits approach to implementing them in practice.

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses the connection between health literacy and lack of trust in science and also addresses allergy concerns toward COVID-19 vaccines.

The 2021 ACAAI Annual Scientific Meeting, taking place virtually and in person in New Orleans, kicks off on Thursday, November 4, by focusing on dermatology and atopic dermatitis and concludes on Monday, November 8, with a final plenary session that addresses updates to several treatment guidelines.

Brian T. Kelly, MD, MA, FACAAI, Midwest Allergy and Asthma Clinic, and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting program chair, discusses how this year’s conference content will demonstrate the joint themes of innovation and diversity, as well as what exciting developments presenters and attendees alike should watch for.

Erika Glenn, Division Head of Sales, Care Management, CVS Health, addressed some of the latest innovations in predictive modeling and data analytics being leveraged by her organization in the management of patients with chronic conditions at the Asembia 2021 Specialty Pharmacy Summit in Las Vegas.

A panel at Asembia 2021 Specialty Pharmacy Summit in Las Vegas addressed challenges in the treatment journey of patients with rare diseases, efforts to improve access to gene therapies, and cost and value considerations for stakeholders.

Oncology drugs are a huge driver of cost, but there’s a lot of innovation happening in the space to improve care and outcomes for patients, said Michelle Booth, PharmD, director of specialty clinical solutions at Magellan Rx Management.

Panelists from a session at Asembia 2021 Specialty Pharmacy Summit in Las Vegas discussed considerations for manufacturers, specialty pharmacies, and payers entering the rare disease and gene therapy market.

The state of value-based contracting in specialty pharmacy was addressed in a panel discussion at Asembia 2021 Specialty Pharmacy Summit in Las Vegas, with speakers touching on the essentials of such agreements, how to optimally integrate them, and future considerations for the pharmaceutical marketplace.

Some policy reforms can help incentivize more use of value-based contracts, but overall an area that needs more work is value-based contracts with pharmaceutical companies, said Steven Peskin, MD, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.

After the public health emergency is over, there will likely remain incentive to keep some administration of specialty therapies at home, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.

Panelists of the opening session at Asembia 2021 Specialty Pharmacy Summit in Las Vegas address emerging shifts in specialty pharmacy, its impact on the health care system, and future implications post pandemic.

At the fully in-person meeting of the Asembia 2021 Specialty Pharmacy Summit, held in Las Vegas, Nevada, attendees will get multiple sessions looking into the future of specialty pharmacy, as well as sessions on hot topics like telehealth and health equity.

Horizon Blue Cross Blue Shield of New Jersey has been involved in a number of value-based cancer care initiatives that will be highlighted during an upcoming Asembia session, said Steven Peskin, MD, MBA, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.

In 2 sessions at the Asembia 2021 Specialty Pharmacy Summit, George Van Antwerp, MBA, managing director, Deloitte Consulting, will provide a look at the future of specialty pharmacy and health equity in pharmacy.

As deductibles for Medicare Part D beneficiaries and enrollment continue to rise, new policies and reconciliation negotiations aimed at lowering costs may hold the key to stabilizing Part D plans, according to presenters at the Academy of Managed Care Pharmacy Nexus 2021 meeting.

Two posters presented at AMCP Nexus 2021 review the high burden of social determinants of health (SDOH) on patients with serious mental illness.

During her presentation at the Academy of Managed Care Pharmacy Nexus 2021 meeting, Aimee Tharaldson, PhD, highlighted the most anticipated specialty pharmacy drugs awaiting FDA approval, including several treatments for cancer and rare diseases.

Novel financial concepts will help to ensure sustainable access to gene and cell therapies, which may help reduce disparities, said Jane F. Barlow, MD, MPH, MBA, senior advisor, FoCUS Project, MIT Center for Biomedical Innovation, and executive vice president and chief clinical officer at Real Endpoints.

There are potential ways that precision medicine could exacerbate disparities, but it should be used to guide people to the right treatments, said Nick Page, chief clinical and strategy officer, and Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, vice president of clinical programs and services, WellDyne.

There are currently no FDA-approved treatments for refractory chronic cough or unexplained chronic cough. At the CHEST Annual Meeting 2021, attendees heard a readout from a durability study as well as pooled analyses from 2 phase 3 trials for gefapixant.

Evan L. Stepp, MD, FCCP, CPE, a pulmonologist at National Jewish Health, discusses an apparent change in attitudes among patients in the wake of 2019’s e-cigarette or vaping use–associated lung injury (EVALI) crisis.

A panel discussion at AMCP Nexus 2021 explored the current biosimilar landscape and level of uptake, with survey results showing payers are accepting of biosimilars and that a majority support nonmedical switching.

There has been a huge shift forward in the understanding of innate and adaptive immune mechanisms that provoke type 2 inflammation in atopic disease and eosinophilic esophagitis, according to a CHEST Annual Meeting 2021 speaker.

A panel of experts highlighted a number of emerging product solutions that can help health plans overcome challenges associated with financing and reimbursing gene and cell therapies and offered insight into how these solutions can be expanded as more therapies enter the market.

Paradoxical bronchospasm, although rare, should be recognized more often in spirometry tests, said pulmonologist Malvika Kaul, MD, who discussed study findings from a population of veterans with chronic obstructive pulmonary disease (COPD) and asthma, where the possibly life-threatening condition was not picked up in lung tests.

Multiple trastuzumab biosimilars were approved and launched very quickly in the United States, which sets up an interesting scenario in the market to see the nuance of having multiple options available, said Cate Lockhart, PhD, PharmD, MS, program, director, Biologics and Biosimilars Collective Intelligence Consortium (BBCIC).

Large health system pharmacies need to first identify their own contributions to health care disparities before identifying areas of opportunity to address the issue, said Aimee Loucks, PharmD, manager, specialty clinical pharmacy programs and formulary, Kaiser Permanente.

A panel of experts at AMCP Nexus 2021 explored multiple ways that health plans and providers can begin to address disparities in health care and offered recommendations on how to implement these tactics effectively.

Nicole Herbst, MD, a pulmonary and critical care fellow, talks about how visitor restrictions and communication practices in intensive care units (ICUs) during the COVID-19 pandemic negatively impacted provider job satisfaction and were linked to job burnout, according to a survey presented at the CHEST Annual Meeting 2021.